Bio-Techne vs Thermo Fisher Scientific: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bio-Techne Corp (TECH)

Q3 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

August 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Latest28 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Q2 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

June 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

25 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

Thermo Fisher Scientific Inc (TMO)

Q3 202620 Jul – 8 Oct 2026

▲2▼1

Thermo Fisher Q3: Strong Q2 Results and New Wins, but China and Tariffs Weigh

Q2 Earnings Beat and Raised Guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating estimates. Management raised full-year guidance, and the stock jumped 8.7% to $572.32 as analysts lifted targets.
This is the main positive force that drove the stock price during the quarter.
New Partnerships and Product Approvals Thermo Fisher announced an ImmuPharma manufacturing partnership, received FDA clearance for the EXENT myeloma test, and formed a Mayo Clinic venture called Precure. These expand its service offerings and add potential revenue streams.
These new business wins support future growth and investor confidence.
Microbiology Sale Completed Thermo Fisher completed the $1.075 billion sale of its microbiology business. The deal frees up cash for other investments but trims near-term revenue, creating a mixed impact on the stock.
This strategic move has both positive and negative implications for the company's financials.
China Weakness and Tariff Uncertainty China's academic and government demand remained weak, Asia-Pacific slightly missed expectations, and tariff uncertainty lingered. HSBC cut its target to $540, a real counterweight to the recovery.
These risks put downward pressure on the stock and limit upside potential.

August 202620 Jul – 8 Oct 2026

▲3▼1

Thermo Fisher's recovery broadens, but China and tariffs weigh

FDA clears EXENT myeloma test The FDA cleared Thermo Fisher's EXENT myeloma test, a new product for diagnosing a type of blood cancer. This opens a fresh revenue stream and shows the company's testing business can grow beyond its current lineup.
New product approval is a fresh positive driver for future sales.
Mayo Clinic Precure venture and new partnerships Thermo Fisher formed a venture with Mayo Clinic called Precure and announced other new products and partnerships. These deals broaden its future revenue sources and show its services remain in demand, supporting the stock.
New collaborations expand future revenue and are new to this period.
Completed $1.075B microbiology sale Thermo Fisher completed the sale of its microbiology business for $1.075 billion. This frees up cash that can be used for other investments or debt reduction, but it also removes some near-term revenue, so the effect is mixed.
Completing a major divestiture is a new event with mixed implications.
China weakness and tariff risks persist China's academic and government demand remains weak, Asia-Pacific missed slightly, and tariff risks continue. HSBC cut its target to $540, highlighting these as real counterweights to the recovery.
These are ongoing risks that cap upside and are new details this period.

Latest20 Jul – 8 Oct 2026

▲4

Thermo Fisher's recovery broadens as new products and deals build

Analysts raise targets after Q2 beat After Thermo Fisher's strong Q2, Simply Wall St lifted its fair value to $631 from $591, and Morgan Stanley, Barclays, BofA and Jefferies raised targets into the $630-650 range. Higher targets pull the stock up because they signal analysts expect more profit ahead. HSBC cut to $540, a real counterweight.
Shows the market's upgraded view of TMO's value after results, a direct price driver.
Microbiology sale completed for $1.075 billion Thermo Fisher finished selling its microbiology business to Astorg for about $1.075 billion in cash plus a $50 million seller note. The unit had $645 million of 2025 revenue. Cash from the sale can fund buybacks or growth areas, but it also removes revenue near term, so the effect is mixed.
A completed major transaction that changes TMO's business mix and cash position.
New products and partnerships widen offerings Thermo Fisher launched the EMPAD G2 electron detector, the Gibco CHO-K1 cell-culture panel, and agreed to resell Evosep's Eno proteomics platform. It also joined a Digital CMC Consortium and expanded cancer-monitoring work. These add future sales in instruments, bioprocessing and proteomics, supporting the stock.
Product launches and deals are the main new growth drivers this period.
International revenue beats, China still a risk June-quarter revenue of $11.99 billion beat expectations, with Europe and other regions ahead of forecasts, though Asia-Pacific fell slightly short. Management said China returned to growth but academic and government demand there stayed weak, and tariff risks remain. Broad recovery supports the stock, but China is a real drag.
Shows the geographic demand picture behind TMO's revenue beat and the key risk.

26 Jul – 15 Sep 2026

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.
This is the core new event that reset expectations for the company's earnings power.
Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.
It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.
FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.
A new regulatory approval expands the product portfolio and future revenue.
Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.
A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

July 202623 Jul – 24 Jul 2026

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.
This is the core new event that answers why the stock is moving now.
Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.
This shows the immediate market reaction and analyst validation, which are key to the price move.
New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.
This is a new contract that adds to the growth story and supports the positive outlook.

23 Jul – 24 Jul 2026

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.
This is the core new event that answers why the stock is moving now.
Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.
This shows the immediate market reaction and analyst validation, which are key to the price move.
New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.
This is a new contract that adds to the growth story and supports the positive outlook.

Q2 202622 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

June 202622 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

22 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.